1. Home
  2. SGP

as of 03-05-2026 3:57pm EST

$26.34
$0.08
-0.30%
Stocks Health Care Medical/Dental Instruments Nasdaq

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Founded: 2019 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 932.9M IPO Year: N/A
Target Price: $47.00 AVG Volume (30 days): 82.4K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $24.71 - $30.56 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Latest SpyGlass Pharma Inc. Common Stock News

SGP Breaking Stock News: Dive into SGP Ticker-Specific Updates for Smart Investing

All SGP News

Share on Social Networks: